Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05539443
Other study ID # IRB00085596
Secondary ID PLACER-02020C3-2
Status Completed
Phase N/A
First received
Last updated
Start date October 11, 2022
Est. completion date September 30, 2023

Study information

Verified date July 2023
Source Wake Forest University Health Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

TEAMS-BP is a multicenter, participant-randomized controlled trial designed to compare the effectiveness of Intensive Tailored Telehealth Monitoring (ITTM) versus Intensive Clinic Management (ICM) on Blood Pressure (BP) control and patient activation for BP management following stroke


Description:

The Feasibility phase will allow for a period in which to pilot implementation and evaluation of all systems for data acquisition, clinical management, and collection of 3-month outcomes. The study uses a parallel, 2-arm design with 1-to-1 randomization to treatment group. Randomization will be performed at the participant level, stratified by center, age (18-74, 75+), and race (Black/African American, non-Black/African American).


Recruitment information / eligibility

Status Completed
Enrollment 74
Est. completion date September 30, 2023
Est. primary completion date September 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Diagnosis of ischemic stroke defined as acute brain, spinal cord, or retinal infarction based on objective evidence on imaging (such as a focal area of restricted diffusion on Magnetic Resonance Imaging [MRI]) in a defined vascular distribution or clinical evidence of focal ischemic injury based on symptoms persisting > 24 hours; or spontaneous hemorrhagic stroke defined as a focal collection of blood within the brain parenchyma that is non-traumatic and identified by brain computed tomography (CT) or brain MRI - Age =18 years - Discharged directly home from acute care or inpatient rehabilitation - SBP>130 at the post-acute clinic visit (within 21 days of discharge) & at Study Visit 1 (within 31 days of discharge) - Able to read and understand English or Spanish - Have access to a functioning smartphone or tablet with broadband access (required for the intervention) - Willing to install and use a study-compatible physical activity monitoring application on their smartphone or smartphone of a qualifying caregiver - Stated agreement to participate in either intervention to which they are assigned and attend all required study visits - Consent to receiving Short Message Service (SMS) required as part of the study interventions - Provision of a signed and dated informed consent form Exclusion Criteria: - Subdural hematoma or subarachnoid hemorrhage - Current participation in another stroke clinical trial precluding dual enrollment - Presence of terminal illness, such as cancer, that limits life expectancy to <1 year - Diagnosis of end-stage renal disease defined as permanent kidney dysfunction requiring the use of hemodialysis or peritoneal dialysis - Pregnancy, lactation or planning to become pregnant - Late-stage Alzheimer's disease or related dementia - Transitioned to a facility such as skilled nursing or long-term care prior to enrollment - Any condition that in the opinion of the study investigator would preclude the participant from being able to safely participate in the trial

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Intensive Clinic Management (ICM)
An in-person clinic management based on the intervention tested among stroke patients in the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial
Intensive tailored telehealth management (ITTM)
A remote-monitoring blood pressure (BP) management strategy incorporating individualized lifestyle coaching and care planning based on the HyperLink telehealth management trial

Locations

Country Name City State
United States Atrium Health Wake Forest Baptist Winston-Salem North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Wake Forest University Health Sciences

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of participants with 3-month SBP control 3 months
Secondary Mean change in systolic blood pressure (SBP) at 3 months Defined as the SBP at baseline (Visit 1) subtracted from the SBP at 3 months (Visit 2). Baseline, 3 month
Secondary Mean change in Partners in Health Scale (PIH) score at 3 months Each of the 11 items on the PIH have eight response options ranging from (0) very good to (8) very poor. To calculate the total PIH score, the raw score is summed and transformed to a range [0,100], with lower PIH scores indicating higher patient activation. Baseline, 3 month
Secondary Proportion of participants eligible among those screened 3 Month
Secondary Proportion of participants providing written informed consent among those eligible Baseline
Secondary Proportion of participants attending both visits among those who are randomized in the study 3 months
Secondary Systolic Blood Pressure Mean Value 3 months
Secondary Proportion of respondents with top score in overall experience on the Research Participant Perception Survey (RPPS) The overall experience (Overall Rating) is rated on a 10-point scale from 0 (Worst) to 10 (Best). The top score is for overall score includes all participants that responded 9 or 10. 3 months
Secondary Proportion of participants billed Proportion of participants for which coaching or remote physiologic monitoring services were billed (at any point during the study) using Current Procedural Terminology (CPT) billing codes. 3 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03753633 - Efficiency of Speech Therapy in Resistant Hypertensive Patients With Mild Obstructive Sleep Apnea Syndrome N/A
Active, not recruiting NCT04646902 - Kynurenine/Tryptophan Ratio in Hypertension Associated to Obstructive Sleep Apnea
Completed NCT03155139 - Primary Aldosteronism In Hypertensive Patients in China
Completed NCT03105531 - Screening for Primary Aldosteronism in a Population of Patients With Hypertension
Completed NCT03246022 - Characteristics of Obstructive Sleep Apnea Syndrome Related Hypertension and the Effect of Continuous Positive Airway Pressure Treatment on Blood Pressure